TCN-213
TCN-213 is a novel chemical compound that has been studied for its potential therapeutic effects in various medical conditions. It is primarily known for its action as a selective modulator of certain neurotransmitter systems in the brain, which makes it a compound of interest in the field of neuropsychopharmacology.
Mechanism of Action[edit | edit source]
TCN-213 is believed to exert its effects by selectively modulating the activity of the glutamate receptors, particularly the NMDA subtype. This modulation can lead to alterations in synaptic plasticity, which is a crucial process in learning and memory. By influencing these pathways, TCN-213 has the potential to impact cognitive functions and has been investigated for its role in treating neurodegenerative disorders.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of TCN-213 includes its absorption, distribution, metabolism, and excretion. TCN-213 is administered orally and has a moderate bioavailability. It is metabolized primarily in the liver, and its metabolites are excreted via the renal route. The elimination half-life of TCN-213 is approximately 6-8 hours, which supports its dosing schedule in clinical trials.
Clinical Applications[edit | edit source]
Research into TCN-213 has focused on its potential use in treating conditions such as Alzheimer's disease, Parkinson's disease, and major depressive disorder. In preclinical studies, TCN-213 has shown promise in improving cognitive deficits and reducing neuroinflammation. However, clinical trials are ongoing to determine its efficacy and safety in humans.
Side Effects and Safety[edit | edit source]
The safety profile of TCN-213 is still under investigation. Common side effects observed in early trials include mild gastrointestinal disturbances and transient headaches. Long-term safety data are not yet available, and further studies are needed to fully understand the risk-benefit ratio of TCN-213.
Research and Development[edit | edit source]
TCN-213 is currently in the early stages of clinical development. Several pharmaceutical companies are involved in its research, aiming to explore its full therapeutic potential. The compound is also being studied in combination with other drugs to assess synergistic effects in treating complex neurological disorders.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
